Y-mAbs Therapeutics (Y-mAbs Therapeutics) Short-Term Debt & Capital Lease Obligation : $0.90 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Y-mAbs Therapeutics Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Y-mAbs Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.90 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Y-mAbs Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.52 Mil.

Y-mAbs Therapeutics Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Y-mAbs Therapeutics's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-mAbs Therapeutics Short-Term Debt & Capital Lease Obligation Chart

Y-mAbs Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.52

1.97

1.78

0.87

0.90

Y-mAbs Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															0.87	0.86	0.83	0.90	0.90

Y-mAbs Therapeutics Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Y-mAbs Therapeutics Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-mAbs Therapeutics Inc (NAS:YMAB) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

230 Park Avenue, Suite 3350, New York, NY, USA, 10169

Website

https://www.ymabs.com

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.

Executives

Thomas Gad	director, officer: President and Chairman	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Biotech Aps Wg	10 percent owner	RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Johan Wedell-wedellsborg	director, 10 percent owner	RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Michael J Rossi	director, officer: President & CEO	230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Vignesh Rajah	officer: SVP and CMO	HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950
Bo Kruse	director, officer: EVP, CFO, Secy & Treas.	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Susan Laura Smith	officer: Senior Vice President, CCO	5 OVERLOOK CT, LAMBERTVILLE NJ 08530
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Juan Moller San Pedro Claus	director, officer: Chief Executive Officer	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Mahiuddin Ahmed	officer: Sr. VP and CSO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Philip Karl Herman	officer: Sr. VP and CCO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Gregory S Raskin	director	C/O MEMORIAL SLOAN KETTERING CANCER CENT, 1275 YORK AVENUE, BOX 524, NEW YORK NY 10065
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169